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Abstract
Background: Alport syndrome (AS) is a progressive renal disease with cochlear and ocular
involvement. The majority of AS cases are X-linked (XLAS) and due to mutations in the COL4A5
gene. Although the disease may appear early in life and progress to end stage renal disease (ESRD)
in young adults, in other families ESRD occurs in middle age. Few of the more than four hundred
mutations described in COL4A5 are associated with adult type XLAS, but the families may be very
large.
Methods: We classified adult type AS mutation by prevalence in the US and we developed a
molecular assay using a set of hybridization probes that identify the three most common adult type
XLAS mutations; C1564S, L1649R, and R1677Q.
Results: The test was validated on samples previously determined to contain one or none of these
mutations. In the US, the test's clinical specificity and sensitivity are estimated to be higher than
99% and 75% respectively. Analytical specificity and sensitivity are above 99%.
Conclusion: This test may be useful for presymptomatic and carrier testing in families with one
of the mutations and in the diagnosis of unexplained hematuria or chronic kidney disease.
Background
Alport syndrome (AS) is a progressive inherited disease
characterized by persistent hematuria that progresses to
ESRD. The disease is often accompanied by progressive
hearing loss and ocular lesions. AS is due to defects in type
IV collagen alpha chain 3, 4 or 5 encoded respectively by
the COL4A3, COL4A4 and COL4A5 genes. The majority
(>80%) of AS is X-linked with mutations found in the
COL4A5 gene [1]. Autosomal recessive and dominant
forms also exist due to mutations in COL4A3 or COL4A4.
More than 400 mutations causing XLAS have been
described in COL4A5 http://www.arup.utah.edu/data
base/ALPORT/ALPORT_welcome.php. Genotype-pheno-
type correlations have been established by several groups
[2-4]. Large rearrangements, nonsense and frameshift
mutations cause juvenile onset disease in most patients.
Other mutations such as some splice variants and glycine
substitutions in the GXY collagen repeats, specifically in
exons 1-20, confer later onset disease [2]. Amino acid sub-
stitutions in the N non-collagenous (NC1) domain of the
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alpha 5 chain were described in families with adult onset
(ESRD at >30 years old) XLAS with or without hearing loss
[5-7].
Among mutations for adult type AS, L1649R was discov-
ered in 9 kindreds and traced to a single common ancestor
in New England more than 200 years ago [6]. C1564S was
discovered in one very large kindred residing in the US
[1]. R1677Q was found in three families of Ashkenazi
Jewish descent [5]. Phenotypes associated with three
mutations (C1564S, L1649R and R1677Q) are distinct
with the effect of C1564S being more severe than L1649R
or R1677Q.
In this manuscript we address the prevalence of these
mutations, in the US among other mutations responsible
for adult type AS and we describe a cost effective and rapid
molecular test targeted to these 3 mutations.
Methods
Adult-type AS was defined as median age of ESRD greater
than 30 years in males. Cases were identified from the
Utah Alport Study. The median age of ESRD in affected
males in kindreds with a known COL4A5 mutation was
calculated by Kaplan-Meier survival analysis (SPSS 16.0
for Mac). For two mutations, no males had reached ESRD.
In these kindreds the median age of ESRD was expressed
as greater than the age of the oldest living affected male.
Gene-carrying males were stratified by mutation inde-
pendently of whether they came from one family or from
several families with the same mutation.
All gene-carriers known by June 2009 were tabulated and
the proportions attributable to each mutation were calcu-
lated. Males were designated as affected (and therefore
gene-carriers) if a mutation had been shown in the indi-
vidual by genetic analysis using any of several methods
[1,5,6,8], or if a mutation had been shown in the kindred
and the individual was on a line of descent for X-linked
inheritance and had hematuria or renal failure. Females
were designated as gene-carriers if a mutation had been
shown in the individual by genetic analysis or if a muta-
tion had been shown in the kindred and the individual
was on the line of descent for X-linked inheritance and
had hematuria, renal failure or was an obligate carrier.
For the molecular assay, DNA, obtained from approved
IRB protocols and described previously [5,6], was used for
validation. Positive samples comprised both males and
females. Nine had the C1564S mutation, 12 the R1677Q
mutation and 13 the L1649R mutation. Samples with
mutations in other COL4A5 exons and one non-affected
male sample were used as confirmed negatives for the tar-
geted mutations. Twenty of these were tested for C1564S
and R1677Q and 17 were tested for L1649R.
Exons 49 (C1564S), 50 (L1649R) and 51 (R1677Q) were
amplified by PCR in a LightCycler instrument (Roche
Applied Science) using 0.5 μM of primers and 0.2 μM of
probes shown in Table 1, 3 mM MgCl2 1× LightCycler
DNA Master HybProbe (Roche Applied Science), UNG
(0.1 unit of AmpErase Uracil N-glycosylase). For each
mutation, probes comprised an anchor probe labeled in
3' with FITC and a reference probe that matches the non -
mutated sequence, labeled in 5' with either LC705
(C1564S and L1649R) or LC640 (R1677Q) and blocked
in 3' with a C3 blocker (Idaho Technology, Salt Lake City,
Utah). Exons 49 and 51 were multiplexed while exon 50
was amplified individually with the following protocol:
After pre-warming the instrument at 94°C for 10 min. and
cooling to 30°C for 1 min., one UNG decontamination
step was performed for 3 sec. at 50°C followed by UNG
enzyme inactivation at 95°C for 5 min. Amplification was
for 60 cycles of 95°C for 0 sec, 60°C for 10 sec and 75°C
for 15 sec. Ramp rate (°C/sec) between the steps were
respectively 20, 20 and 2. After amplification, the PCR
product was melted as follow; 94°C for 30 seconds fol-
lowed by cooling and holding at 45°C for 2 minutes.
Temperature was then increased to 85°C at a rate of
0.1°C/sec while fluorescence was recorded in both the F2
(LC640) and the F3 (LC705) channels of the instrument
in presence of the color compensation file. Negative deriv-
ative of melting curves were calculated using the LCDA 3.5
software and Tm of the probes was determined.
Results and Discussion
Mutations at 3 loci account for the majority of all cases of 
adult-type AS in the US
Mutations in Col4A5 were determined in several hundred
adult type XLAS known or inferred gene -carriers (Table
2). Twenty two mutations were determined among which
9 were previously reported but not analysed for pheno-
type. L1649R mutation is found in 48.6% of all gene-car-
Table 1: primers and probes sequences for each mutation
C1564S
Forward primer: 5' gaaggcttccaatgaagcag
Reverse primer: 5' tgatgacaaatgcaaggaaga
Anchor probe: 5' ctgactgtgaactgcgatcaccacagctggagctt-FITC
Reference probe: 5'LC705-acatactgcaCatctggtaaagg-C3 block
L1649R
Forward primer: 5' tttcgttcagctcccttc
Reverse primer: 5' tataagcactttacctgaacatgtctg
Anchor probe: 5' ggtacctgtaactactatgccaactcctaca-FITC
Reference probe: 5'LC705-cttttggcTggcaactgt-C3 block
R1677Q
Forward primer: 5' ccagaaaatgtggatctgattg
Reverse primer: 5' ttggggacaatgagacactg
Anchor probe: 5' cacaaaaggaattcttcaaaatgttatgtcctcttcat-FITC
Reference probe: 5'LC640-cacacttgacatCggctaattc-C3 blockBMC Nephrology 2009, 10:38 http://www.biomedcentral.com/1471-2369/10/38
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riers for adult-type AS, the C1564S mutation in 17.4%
and R1677Q mutation in 7.5%. When C1564R and
R1677P are included, missense mutations at positions
1564, 1649, and 1677 account for 76.4% of all mutant
genes for adult-type AS in our kindreds.
Information in the Utah Alport Study has been collected
since 1949 when Tyler and Perkoff began to investigate
nephritis in four related men who were subsequently
shown to carry the C1564S mutation [9]. There is obvious
potential for ascertainment bias favouring larger numbers
in this kindred because the C1564S family was the first to
Table 2: Median age of ESRD in affected males and numbers of known gene-carriers in adult type Alport syndrome
COL4A5 mutation
[ref of previously published mutation]
ESRD age Male Female Total % of total
leu1649arg [6] 39 150 222 372 48.6
cys1564Ser [1] 32 52 81 133 17.4
arg1677gln [5] 50 19 38 57 7.5
gly1170ser 38 13 11 24 3.1
c.2476delC 44 11 12 23 3.0
gln1234ter 42 7 16 23 3.0
c.1424-20 T>A 32 7 12 19 2.5
cys1564arg 33 9 9 18 2.4
pro1584 leu 34.5 6 9 15 2.0
arg1563gln [2] 34.5 5 8 13 1.7
gly1030ser [10] 38 9 3 12 1.6
c.687+1G>A 33 7 4 11 1.4
gly763glu 42 5 3 8 1.0
gly548asp 45 6 2 8 1.0
gly1244asp [8] 57 3 3 6 0.8
arg1677pro [8] 37.5 2 2 4 0.5
gly295asp [8] 49.5 3 1 4 0.5
gly719arg >38 2 2 4 0.5
c.3554 -3C>G [10] 31 2 2 4 0.5
gly533glu 32 1 2 3 0.4
c.4177delC 35 2 0 2 0.3
gly325gln >41 1 1 2 0.3
Total 322 443 765 100.0BMC Nephrology 2009, 10:38 http://www.biomedcentral.com/1471-2369/10/38
Page 4 of 6
(page number not for citation purposes)
be studied and there has been more time to ascertain
members than in other kindreds. We cannot completely
exclude ascertainment bias, but during the 60 years of the
Utah Alport Study cases have accumulated from across the
whole of the United States and for most of this time our
center was the only one collecting cases on a systematic
basis. There has been ample opportunity to discover a
large proportion of the kindreds with AS in the US. As an
example, 22 apparently unrelated families with the
L1649R mutation have come to light and this is now the
most prevalent mutation. Twelve of these families were
shown by haplotype analysis to have arisen from a com-
mon ancestor [6]. Although it is possible that other large
kindreds exist but have not come to light over 60 years of
data collection, this seems unlikely. It is also possible that
there are as yet unrecognized branches of known families.
Ascertainment bias within kindreds is shown in the ratio
of females to males identified. For an X-linked condition
at equilibrium there will be twice as many female as male
gene-carriers. The overall F:M proportion in our study was
1.39. It was higher in the 3 largest kindreds at 1.48, 1.56,
and 2.0 respectively, but only 0.77 in the families with 4
or fewer identified gene-carriers. Gender-specific ascer-
tainment bias is expected in an X-linked condition
because males are more severely affected and thus come to
notice.
Despite inaccuracies introduced by ascertainment bias,
our data are the only systematic compilation of adult-type
AS mutations in the US. We believe that they provide a
reasonable approximation of the relative frequencies of
different adult-type mutations.
Molecular assay for the detection of L1649R, R1677Q and 
C1564S mutations
We have developed a molecular assay using fluorescently
labeled hybridization probes that detect the three main
US mutations. The C1638Y mutation recently described
in New Zealand [7] and other rare mutation (Table 2) are
not included in this test. The assay uses melting curve
analysis of three allele specific hybridization probes. Melt-
ing analysis of the C1564S probe (Figure 1) shows one
single melting curve in the four positive males with a
melting temperature (Tm) of 56.7°C, two melting curves
in the five heterozygotes females (Tms = 56.7°C and
65.8°C), and a single melting curve in 22 samples nega-
tive for the mutation (Tm = 65.8°C). The curves corre-
spond to the dissociation of the probe with the mutant
and normal allele, respectively. Genotyping of this locus
was 100% accurate.
The L1649R probe was tested on nine positive males, four
positive females and 17 samples with other mutations in
COL4A5. Melting analysis of the probe revealed a single
peak (Tm = 57.4°C) in positive males, two peaks in heter-
ozygous females (Tms = 57.4°C and 65.3°C) and a single
peak in samples without the mutation (Tms = 65.3°C).
Accuracy was 100%.
The R1677Q mutation was analyzed in six positive males,
five carrier females and a positive sex-undetermined sam-
ple. Twenty-two samples without the mutation were also
tested. Two of these had mutations in the same codon as
R1677Q (R1677X [10] and R1677P [8]) and are associ-
ated with juvenile XLAS (unpublished). The melting peak
corresponding to the presence of the mutation is 57.4°C
while the melting peak of the normal allele is 65.1°C. The
R1677X mutation was detected by a melting curve at
60.0°C and the R1677P mutation at 56.3°C, both distin-
guishable from the targeted mutation. All positives and
negative samples were correctly identified by the assay.
Precision of the assay was performed by analyzing a sam-
ple of each genotype in triplicate in one experiment
(within run variation) and in five independent experi-
ments (between run variation). Values of Tms and differ-
ence of Tms between the curves (in heterozygous females)
were used to determine the precision of the assays. Two
standard deviations were calculated from the averages and
did not exceed 0.5°C for Tms and 0.25°C for delta Tms.
The assay identified all the targeted mutations present in
the positive samples and none in negative samples; it has
accuracy, analytical sensitivity and specificity above 99%.
Because the mutations are familial and are carried on sin-
gle haplotypes, it is unlikely that unreported polymor-
phisms under the PCR primers or the probes will affect the
analytical sensitivity or specificity of the assay.
Males with one COL4A5 mutation are predicted to be
affected with AS while women with one mutation are car-
riers and may or may not develop symptoms. The
C1564S, which likely disrupts the collagen IV network by
disabling formation of a disulfide bond is the most severe
of the three. Fifty percent of males positive for C1564S are
expected to have ESRD by age 32 and hearing loss by age
25. The mutation L1649R substitutes a neutral amino acid
for a charged amino acid in the NC1 domain. ESRD is
expected for 50% of L1649R positive males by age 38 and
hearing loss by age 45 [6]. Typical age of ESRD in males
with the R1677Q mutation is 38 years [5].
Other mutations associated with adult type AS, Table 2
and [2,7] or with juvenile type AS will not be detected.
Clinical sensitivity for adult type XLAS in U.S. Caucasian
population is estimated to be around 75% and clinical
specificity is 99%. Other testing approaches such as
sequencing and detection of duplications and deletions inBMC Nephrology 2009, 10:38 http://www.biomedcentral.com/1471-2369/10/38
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Genotyping of C1564S, L1649R, and R1677Q by melting curve analysis Figure 1
Genotyping of C1564S, L1649R, and R1677Q by melting curve analysis. Each graph analyzes one of the mutations 
with DNA from a positive male (dotted line), a female carrier (black line), a normal individual (grey line) and a no template con-
trol (thin grey line). Fluorescence on the Y axis is the negative derivative of fluorescence in function of temperature. Positions 
of the peaks indicate the dissociation of the probes with a given allele. As probes are homologous to the normal allele, lower 
Tms correspond to the mutant alleles and higher Tms to the normal allele.
	

	









	
	   
 
  






























 
!"#	

	



	




	   
 
  


























$



 
#%%&	

	






	







	   
 
  






























 Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Nephrology 2009, 10:38 http://www.biomedcentral.com/1471-2369/10/38
Page 6 of 6
(page number not for citation purposes)
COL4A5, COL4A3 and COL4A4 need to be used to detect
all genetic mutations implicated in AS.
Conclusion
This assay is designed to detect mutations responsible for
the majority of adult type AS in the US. It is recommended
for diagnostic, pre-symptomatic, or carrier testing of indi-
viduals from families known to carry one of the COL4A5
mutations tested: C1564S, L1649R or R1677Q. Adult type
AS is likely substantially under-diagnosed because the X-
linked pattern of inheritance frequently conceals the
familial nature of the disease and because hearing loss is
subtle in many cases. This assay may help elucidate other-
wise unexplained hematuria or chronic kidney disease in
men, and unexplained hematuria in woman with a family
history of chronic kidney disease.
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